%0 Journal Article
%T Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer¡¯s disease
%A Claus Thamer
%A Glen Wunderlich
%A Lutz Fr£¿lich
%A Michael Roehrle
%A Miguel Garcia
%A Jr
%J Archive of "Alzheimer's Research & Therapy".
%D 2019
%R 10.1186/s13195-019-0467-2
%X Putative mode of action of phosphodiesterase type 9 inhibition by BI 409306. Ca2+, calcium; cGMP, cyclic guanosine monophosphate; GTP, guanosine triphosphate; LTP, long-term potentiation; NMDA-R, N-methyl-D-aspartate receptor; NO, nitric oxide; NOS, nitric oxide synthase; PDE9, phosphodiesterase type 9; sGC, soluble guanylate cyclase. Figure adapted from Moschetti et al. [7
%K Alzheimer¡¯s disease
%K Treatment efficacy
%K Neuropsychological test battery
%K Phosphodiesterase type 9 inhibitor
%K Prodromal stage
%K Safety
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371616/